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Abstract
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is defined
based on recent alcohol consumption; however, remote or lifetime alcohol
consumption is not taken into account. It is not known whether lifetime
alcohol consumption contributes to the severity of disease in patients with
NAFLD. To determine the effect of lifetime alcohol consumption on the
histological severity in patients with NAFLD. Patients & Methods: Adults
>18 years of age with presumed NAFLD and alcohol consumption <40 g/
week were enrolled. Lifetime alcohol consumption was determined using a
questionnaire. Patients with a history of long-term alcohol abuse or depen-
dence were excluded. A liver biopsy was reviewed by a single pathologist in a
blinded fashion. Demographic, clinical and histological findings were com-
pared in those who had regular alcohol consumption and those who did
not. Results: A total of 77 patients had fatty liver on biopsy. Fifty-two
patients had a history of regular alcohol consumption. The median lifetime
cumulative alcohol intake was 24 gram-years. On multivariable analysis,
increasing age (OR 1.07, 95% CI 1.01–1.14) was associated with severe liver
disease, whereas alcohol consumption of ≥24 gram-years was associated with
less severe disease (OR 0.26, 95% CI 0.07–0.97, P = 0.04). Patients who con-
tinued to consume alcohol or had been abstinent for ≤1 year had less severe
disease. Conclusion: Some degree of regular alcohol consumption over the
course of a lifetime compared to minimal intake appears to have a protective
effect on the histological severity of liver disease among patients with strictly
defined NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is now rec-
ognized as one of the most common forms of chronic
liver disease in developed countries with an estimated
prevalence of 10–24% in the general population (1–3).
Obesity, type 2 diabetes mellitus (DM) and dyslipida-
emia are common risk factors for NAFLD. A diagnosis
for NAFLD is considered in patients with elevated liver
enzymes and/or fatty liver on imaging, who have no
significant alcohol consumption and no other causes of
chronic liver disease. There is variability in the cut-off
value used to determine the significance of current
alcohol consumption. Lifetime alcohol consumption is
not taken into consideration when NAFLD is clinically
suspected. The range of current alcohol intake that has
been proposed for this cut-off is 10 g per day or less to
20–40 g per day in men and 20 g per day in women. It
has been suggested that a reasonable cut-off would be
20 g per day, acknowledging that there will be uncer-
tainty in the grey areas of this limit (4).
It is well known that in patients with chronic hepati-
tis C, lifetime alcohol consumption is an independent
risk factor for histological disease progression including
the development of cirrhosis (5, 6). Studies on the role
of ongoing alcohol consumption in patients with NA-
FLD have reported variable results with some studies
showing a protective effect while others showing a role
for disease progression similar to that seen in chronic
hepatitis C (7–11). However, the effect of lifetime alco-
hol consumption on the overall disease severity in
patients with clinically and histologically well-defined
NAFLD has not been reported. The aim of this study
was to determine if the cumulative lifetime alcohol con-
sumption influences the overall histological severity in
patients with NAFLD.
Material and methods
Patients
Adult patients seen in the general Hepatology clinic at
the University of Michigan who were clinically sus-
pected of having NAFLD were enrolled in a prospective
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study between March 2003 and November 2004. The
study was approved by the Institutional Review Board at
our medical centre and all patients signed an informed
consent to participate in the study.
The main inclusion criteria were as follows: (i)
Patients with clinically suspected NAFLD based on per-
sistent elevation in aminotransferase levels (>1.5 upper
limit of normal on two or more occasions at least
3 months apart) and/or radiological evidence of fatty
liver; (ii) A liver biopsy performed within 1 year of en-
rolment into the study; and (iii) Patients should be able
and willing to provide written informed consent for the
study.
Patients were excluded from the study for the follow-
ing reasons: (i) Other causes of chronic liver diseases;
(ii) Alcohol use of more than 40 g/week (≥5 drinks/
week) within the past 12 months or a history of long-
term alcohol abuse or dependence in the past; (iii) Use
of medications reported to cause steatosis (including
amiodarone, steroids, tamoxifen, valproic acid, metho-
trexate, iv tetracycline) within the past 3 months or
greater than 6 months in the past 2 years; (iv) Weight
reduction surgery within 1 year or a history of jejuno-
ileal bypass; (v) Weight loss medication or participation
in weight loss programme in the past 3 months; and
(vi) Evidence of hepatic decompensation, HIV antibody
positive, pregnant or breast feeding.
Study design
Adult patients suspected of NAFLD were enrolled into
the study after written consent was obtained. Medical
documents were reviewed focusing on the inclusion and
exclusion criteria. Anthropometric evaluation was per-
formed and lifetime alcohol consumption history was
obtained by interview using the Skinner Lifetime Drink-
ing History. The per cent body fat was estimated by
bioimpedance analysis (BIA) using the RJL Systems
Body Composition Analysis system, which is a simple
technique of measuring body fat. The presence of meta-
bolic syndrome was defined by the National Cholesterol
Education Program (NCEP) Expert Panel on Detection
Evaluation and Treatment of High Blood Cholesterol in
Adults (ATP III) (12). The homeostasis model assess-
ment (HOMA) to calculate insulin resistance (IR)
[HOMA = (insulin (lU/ml) * glucose (mmol/L))/22.5]
was utilized. A HOMA value of 2.0 or greater was
defined as IR (13).
Liver biopsies were performed within 1 year of enrol-
ment and reviewed by a single pathologist blinded to
the clinical history. The histological features of NAFLD
were scored according to NASH Clinical Network
Scoring System by Kleiner and Brunt (14). In brief, the
presence and severity of steatosis (0–3), lobular inflam-
mation (0–3), hepatocyte ballooning (0–2) and fibrosis
(0–4) were scored. The NASH activity score (0–8) is the
sum of steatosis, lobular inflammation and ballooning
and the Global NASH score (0–12) is the sum of the
NASH activity score and fibrosis. The presence of bridg-
ing fibrosis or cirrhosis was defined as having ‘severe
histological disease’ in this study.
Lifetime alcohol consumption
The Skinner Lifetime Drinking History is a structured
interview that estimates alcohol consumption through-
out an individual’s lifetime (15). The interview begins
with determining if the patient consumes more than
one drink (beer, liquor, wine, wine cooler) per month
for 1 year or more than three drinks a day for three con-
secutive days over the course of their life. ‘Abstinence’
from alcohol was defined as those who consume less
than this predetermined amount. For each time period
that the drinking pattern changed, the duration,
frequency, average and maximum quantity each time
alcohol was consumed, the style of drinking (binge,
weekend, frequent, occasional), variability in consump-
tion, type of beverage and life events that may have
affected drinking patterns were obtained.
The total amount of alcohol consumption was
expressed as gram-years for each drinking pattern.
Gram-years of consumption were calculated by multi-
plying the amount of alcohol consumed (grams) per
day by the duration of a particular drinking pattern
(years). The total amount of alcohol consumed over a
lifetime was determined by adding the gram-years for
each drinking period. The duration of abstinence from
alcohol was determined by subtracting the age that the
patient last drank less than one alcoholic beverage per
month in a year or less than three drinks for three
consecutive days from the patients’ age at enrolment.
Statistical analysis
Using a t-test for continuous variables and chi square
analysis for categorical variables we compared patients
with a history of drinking and those who abstained.
Correlation between histology and variables was anal-
ysed by Pearson’s correlation coefficient. Statistical
analysis was performed using SAS 9.1 (SAS Institute Inc.,
Cary, NC, USA).
Results
The study population consisted of 77 patients with
histologically confirmed NAFLD who also had had com-
pleted the lifetime alcohol consumption survey at the
time of initial enrolment into the study. The characteris-
tics of the 77 patients are in Table 1. Forty-three
patients (56%) were women and 52 (68%) were obese
(Body mass index ≥30 kg/m2). The presence of meta-
bolic syndrome as defined by ATP III (Adult Treatment
Panel III, Third report of the expert panel on detection,
evaluation and treatment of high blood cholesterol in
adults) criteria was seen in 39% of patients (n = 30).
Sixty-seven patients (87%) had evidence of insulin
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resistance defined as HOMA (homeostasis model assess-
ment) index ≥2.0. Overall, histological disease was mild
in these patients with a mean NASH activity score of 3.9
(range 1–7) and mean global NASH score of 5.4 (range
1–9). Severe liver disease (bridging fibrosis or cirrhosis
on liver biopsy) was seen in 17 patients (22%).
Lifetime alcohol consumption
The overall median alcohol consumption among the 77
patients with NAFLD was 24 gram-years (range 0–2251).
Although the patients were recruited into the study
based on the definition of <40 g per week, the patient
with the alcohol consumption 2251 gram-year was the
outlier – once recruited the patient gave this history on
the lifetime alcohol questionnaire. Removing the patient
from the analysis did not change the findings median
values reported. Those who consumed equal to or more
than 24 gram-years were more likely to be men (73%
vs. 40%, P = 0.01), had significantly lower per cent total
body fat (BIA% fat 33 ± 12 vs. 43 ± 12, P = 0.001) and
lower serum total cholesterol levels (194 ± 42 vs.
215 ± 58 mg/dl, P = 0.05), when compared to patients
who consumed <24 gram-years (Table 1). In addition,
patients who consumed ≥24 gram-years had signifi-
cantly lower fibrosis scores on liver histology (1.2 ± 1.0
vs. 1.8 ± 1.2, P = 0.03). Although there was a trend
towards lower insulin resistance in the higher con-
sumption group (HOMA index values 5.2 ± 3.6 vs.
6.1 ± 3.9), this difference was not statistically significant
(P = 0.31).
We also compared patients with lifetime alcohol
consumption at cut-off values of 10 gram-years and
40 gram-years. In both settings, the per cent total body
fat (BIA%) and the fibrosis score remained significantly
lower in the group that consumed more alcohol (data
not shown).
Table 2 compares patients who consumed alcohol vs.
those who had had abstained from alcohol in their life-
time (non-drinkers). Twenty-five patients (32%) were
abstinent from alcohol and were more likely to be
women (83% vs. 44%, P = 0.0001) and had a higher
body fat percentage measured by bioimpedance assay
(44.9% vs. 34.5%, P = 0.0003). There was, however, no
statistically significant difference in the overall NAFLD
histology assessment (steatosis, lobular inflammation
and hepatocyte ballooning grades or fibrosis stage)
between the two groups.
Factors associated with severe liver disease (Fibrosis
stage 3-4)
Severe liver disease (fibrosis stage 3-4: F3/F4) was asso-
ciated with increasing age, per cent total body fat (BIA
%), serum aspartate aminotransferase and alkaline
phosphatase levels and NASH histological feature of bal-
looning (P < 0.05 – < 0.001). As seen in Tables 1 and 2,
the number of patients who were non-drinkers or had
lifetime alcohol consumption below less than 24 gram-
years was significantly higher in the F3/F4 group com-
pared to the group with less severe (F0-2) liver disease
with regards to fibrosis severity. The presence of severe
liver disease was inversely related to the quantity of life-
time alcohol consumption (≥24 vs. < 24 gram-years,
relative risk 0.32, P = 0.005). In multivariate analysis,
as shown in Table 3, after controlling for other charac-
teristics including age, gender, BMI, BIA% fat, HOMA-
IR index, liver enzymes and selected histological
features, the independent risk factors for severe liver dis-
ease were an increase in age (years) and smaller quanti-
ties (<24 gram-years) of lifetime alcohol consumption.
Patients who consumed equal to or above the median
level of alcohol during their lifetime had a significantly
lower risk of bridging fibrosis or cirrhosis (OR: 0.26,
95% CI: 0.07–0.97, P = 0.046). In addition, the protec-
tive effect of alcohol consumption was even seen in
patients consuming above the lower cut-off level of
10 gram-years (odds ratio 0.24, 95% CI: 0.07–0.89,
P = 0.03) when controlling for other factors, however,
it was no longer significant above the higher cut-off
value of ≥40 gram-years of lifetime alcohol consump-
tion (data not shown).
Table 1. Clinical, Demographic, biochemical and histological char-
acteristics of patients with ≥ or < than 24 gram-years Lifetime alco-
hol consumption
≥24 gm-yrs
(n = 40)
<24 gm-yrs
(n = 37) P-value
Age (years) 46 ± 11 48 ± 12 0.35
Gender (female %) 40 73 0.01
BMI (kg/m2) 32 ± 7 34 ± 6 0.33
Waist-Hip ratio 0.9 ± 0.07 0.9 ± 0.07 0.66
BIA% fat 33 ± 12 43 ± 12 0.001
Metabolic syndrome (%) 37 54 0.22
HOMA index 5.2 ± 3.6 6.1 ± 3.9 0.31
Cholesterol (mg/dl) 194 ± 42 215 ± 58 0.05
TG (mg/dl)* 186 ± 97 220 ± 259 0.45
Insulin (lU/dl)* 20 ± 11 22 ± 11 0.44
Glucose (mg/dl)* 99 ± 17 104 ± 22 0.22
ALT (IU/dl) 78 ± 37 73 ± 59 0.68
AST (IU/dl) 50 ± 24 56 ± 43 0.44
Alk Phos (IU/dl) 88 ± 23 106 ± 51 0.05
Histology (NASH-CRN scoring system)
Steatosis (0–3) 1.8 ± 0.8 2.0 ± 0.8 0.27
Lobular inflammation (0–3) 1.5 ± 0.8 1.5 ± 0.8 0.71
Ballooning (0–2) 0.5 ± 0.5 0.6 ± 0.5 0.56
NASH activity (0–8) 3.8 ± 1.5 4.1 ± 1.3 0.30
Fibrosis (0–4) 1.2 ± 1.0 1.8 ± 1.2 0.03
F3/F4 (n) 4 13 0.0001
Global NASH (0–12) 5.0 ± 1.9 5.8 ± 1.9 0.06
*TG, insulin, glucose are fasting measurements.
Data expressed as Mean ± SD values, n (%).
BMI, Body mass index; BIA, bioimpedence analysis (per cent total body
fat); HOMA, homeostasis model assessment; TG, triglyceride; ALT, ala-
nine aminotransferase; AST, aspartate aminotransferase; NASH-CRN,
NASH Clinical Research Network scoring system.
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Duration of abstinence from alcohol
Forty-three patients had a history being of abstinent
from alcohol for ≤1 year of enrolment into the study,
whereas 34 patients had a history of being abstinent
from alcohol for over a year prior to enrolment. Those
who had been abstinent for more than a year had a
significantly higher per cent total body fat (BIA%
41.2 ± 12.4 vs. 33.6 ± 12.4, P = 0.01) and also a higher
fibrosis score on liver biopsy (1.7 ± 1.2 vs. 1.2 ± 1.0,
P = 0.04) compared to those who were still drinking or
were abstinent for ≤1 year. There was a tendency among
the patients with a longer duration of abstinence from
alcohol consumption to have a higher BMI, HOMA and
serum triglyceride levels although the differences
between the two groups were not statistically different
(P > 0.05). We also compared patients with a longer
duration of abstinence from alcohol consumption
(≤5 years vs. >5 years). The per cent total body fat was
significantly higher (BIA% 41.7 ± 12.4 vs. 34.4 ± 12.5,
P = 0.01) and there was a trend towards a higher fibro-
sis score (1.8 ± 1.2 vs. 1.3 ± 1.0) although this was not
statistically significant (P = 0.07) in those patients who
were abstinent for ≤5 years compared to those who were
abstinent for >5 years.
Discussion
The acceptable criteria to define nonalcoholic fatty liver
disease (NAFLD), which was also used in this study,
were alcohol consumption of less than 40 g a week, no
history of alcohol abuse or dependence and exclusion of
other causes of chronic liver disease. With these criteria,
we were able to show that over a lifetime, some amount
of regular alcohol consumption has a protective effect
on the histological severity in individuals with NAFLD.
In this study, patients who had equal to or higher than
median levels (24 gram-years) of lifetime alcohol con-
sumption and those consuming any amount of alcohol
regularly (ongoing or within the past 1 year) had a sig-
nificantly lower risk of fibrosis compared to those who
consumed less alcohol or had abstained from alcohol
for longer durations. Furthermore, the protective effect
of alcohol consumption was seen at levels as low as
10 gram-years of lifetime alcohol consumption. How-
ever, this protective effect was no longer seen when the
alcohol consumption was >40 gram-years in our patient
population suggesting that there may be a threshold
protective effect of alcohol (both below and above a
certain amount consumed) on the overall histological
disease severity/progression in NAFLD. For example, for
a 50-year old patient, 0.3 alcoholic beverages per day or
2.4 alcoholic beverages per week (10 gram-years at the
age of 50) may have a protective effect and 1.4 drinks
per day or 10 drinks per week (40 gram-years) would
not have a protective effect.
Recently there have been several reports showing that
alcohol consumption especially wine in modest
amounts may lead to a decrease in prevalence of NAFLD
and or risk of NASH, suggesting the beneficial role of
alcohol in some individuals at risk (7–9). Other studies
have shown that mild to moderate alcohol consumption
is associated with a lower prevalence of the metabolic
syndrome (16–19). None of the studies have assessed
the role of lifetime alcohol consumption as was done in
this study. In the study by Dunn et al., when comparing
7211 non-drinkers with 945 modest wine drinkers, the
Table 2. Clinical, demographic, biochemical and histological char-
acteristics of all patients diagnosed with NAFLD and those with and
without previous alcohol consumption
All
(N = 77)
Alcohol
use
(N = 52)
Abstinent
(N = 25) P-value
Age (years) 46.9 45.8 49.1 0.26
Sex (Female%) 56 42 84 0.0001
BMI (kg/m2) 33.0 32.7 33.8 0.44
Waist-Hip ratio 0.94 0.94 0.93 0.74
Metabolic syndrome
(%)
39 39 40 0.90
BIA (% fat) 37.9 34.5 44.9 0.0003
Systolic BP (mmHg) 128 129 126 0.35
Diastolic BP (mmHg) 76 77 74 0.16
Cholesterol (mg/dl) 204 201 211 0.40
HDL (mg/dl) 54 55 51 0.65
LDL (mg/dl) 115 116 116 0.97
TG (mg/dl)* 202 191 225 0.59
Insulin (UU/dl)* 21.3 20.4 23.4 0.28
Glucose (mg/dl)* 101 101 103 0.72
HOMA index 5.6 5.3 6.2 0.36
ALT (IU/dl) 76 74 69 0.38
AST (IU/dl) 54 54 55 0.91
Alk Phos (IU/dl) 97 94 101 0.43
Histology (NASH-CRN scoring system)
Steatosis score (0–3) 1.9 1.8 2.0 0.45
Lobular
inflammation (0–3)
1.5 1.5 1.6 0.45
Ballooning (0–2) 0.5 0.5 0.6 0.19
NASH activity (0–8) 3.9 3.8 4.2 0.18
Fibrosis score (0–4) 1.5 1.4 1.8 0.17
F3/F4 (n) 8 9 0.04
Global NASH (0–12) 5.4 5.1 5.9 0.13
*TG, insulin, glucose are fasting measurements.
Data expressed as Mean values, n (%).
BMI, Body mass index; BIA, bioimpedance analysis (per cent total body
fat); BP, blood pressure; HDL, high density lipoprotein; LDL, low density
lipoprotein; TG, triglyceride; HOMA, homeostasis model assessment;
AST, aspartate aminotransferase;ALT,alanine aminotransferase; NASH-
CRN, NASH Clinical Research Network scoring system.
Table 3. Associations with severe liver disease (Fibrosis stage 3–4)
found in Multivariable Logistic Regression
Characteristics Odds ratio 95% CI P-value
Age 1.07 1.01–1.14 0.027
Gram-years (≥24 vs. <24) 0.26 0.07–0.97 0.046
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prevalence of suspected NAFLD based on NHANES lab-
oratory criteria for elevated aminotransferase values was
3.2% among non-drinkers compared to only 0.4%
among modest wine drinkers (8). Using the recent
healthy subject cut-off values, the prevalence of sus-
pected NAFLD was 14.3% and 8.6%, respectively, in the
two groups with an adjusted odds ratio of 0.51 (95% CI
0.33–0.79) among modest wine drinkers (8). In this
study, we did not assess the type of alcohol consump-
tion among our patients. In another study of 1177 male
subjects 20–59 years of age, light to moderate alcohol
consumption was associated with lower prevalence of
abnormal transaminases suggestive for NAFLD (7). In
the same study, there was also an age-related effect
where moderate alcohol consumption was associated
with decreased odds of abnormal transaminases among
the younger age (<41 years) group. Light consumption
was associated with decreased odds and excess con-
sumption was associated with increased odds of abnor-
mal transaminases in the older age (≥41 years) group.
In addition, during a follow-up period of up to 5 years,
moderate alcohol consumption was associated with a
decreased incidence of hypertransaminasemia compared
to those with none or minimal consumption (adjusted
hazard ratio 0.4, 95% CI: 0.1–0.9, P = 0.02) (7).
Other studies have shown a relationship between
alcohol consumption and presence of fatty liver among
individuals clinically suspected of NAFLD or those
being investigated for abnormal liver enzymes among
whom, alcohol intake was measured along with perfor-
mance of ultrasound to detect presence of fatty liver
(20–24). Majority of these studies are cross-sectional
population-based studies from Japan where fatty liver
was diagnosed based on ultrasound and histological
information is not available. Nearly all these studies
have shown a protective effect on the prevalence of
NAFLD as diagnosed by ultrasound in individuals
consuming variable amounts of alcohol.
Very few studies with histological information have
been published assessing the role of alcohol consump-
tion and histological severity in NAFLD. A recent study
by Cotrim and colleagues in contrast to this study was
performed among morbidly obese individuals undergo-
ing bariatric surgery (Cotrim HP et al. 2009) (25). In
this cross-sectional study from USA, there was no effect
of alcohol consumption on steatosis and/or inflamma-
tion and fibrosis among morbidly obese individuals
with fatty liver disease. The only significant finding
was that insulin resistance appeared to be lower only
among individuals with only light alcohol consumption
(alcohol intake less than 20 g/day).
A few studies have shown that alcohol consumption
is associated with progression of fibrosis in patients
with NAFLD (10, 11) while some have shown no sig-
nificant effect (25). Dixon et al. showed that in obese
patients undergoing gastric bypass surgery and who
had alcohol consumption of less than 200 g per week,
the odds ratio for having NASH was 0.35 in alcohol
consumers vs. non-consumers (9). However, when
alcohol consumption was controlled for insulin resis-
tance and diabetes, alcohol consumption did not
appear to be an independent predictor of NASH. In
the study of Ekstedt and colleagues, 71 patients with
biopsy proven NAFLD were re-evaluated after a mean
duration of 13.8 years with a repeat liver biopsy (10).
In this study, the investigators assessed weekly alcohol
consumption and also frequency of episodic drinking.
Significant fibrosis progression, defined as increase in
≥1 fibrosis stage or development of end-stage liver
disease, was seen in 17 patients (24%). Patient with
fibrosis progression were more likely to have a history
of heavy episodic drinking (defined as > 60 g of alco-
hol in men and 48 g in women consumed on one
occasion) and also a trend towards having higher
weekly consumption of alcohol. Heavy episodic drink-
ing was an independent risk factor for significant fibro-
sis progression along with the presence of insulin
resistance in these patients (10). On the basis of the
definition, we used for clinically suspected NAFLD in
this study, patients consumed much less alcohol and
therefore the effects of episodic heavy alcohol con-
sumption on disease severity could not be assessed in
our patients. The role of alcohol intake on the initial
histological presentation as investigated in our study,
however, was not available in this study.
It is clear based on most studies published to date
that whereas mild to modest alcohol consumption
may have a protective effect compared to minimal or
no alcohol consumption, higher amounts of alcohol
may have no effect or even a detrimental effect on
fibrosis progression. This suggests that there may be a
threshold effect of alcohol consumption on the fibrosis
severity in patients with NAFLD. To our knowledge,
ours is the only study that assessed the role of life-time
alcohol consumption in a population of histologically
confirmed NAFLD. In our own study, the number of
patients who were non-drinkers was significantly
higher in the F3/F4 group compared to the group with
less severe (F0-2) liver disease with regard to fibrosis
severity (P = 0.039). Patients with lifetime alcohol con-
sumption of at least 10 gram-years had a significantly
lower prevalence of severe disease even after control-
ling for other factors such as insulin resistance
whereas, above 40 gram-years, this protective effect
was no longer seen. Another interesting finding in this
study was that patients who had a longer duration of
abstinence also had more severe fibrosis suggesting
that some amount of regular alcohol may be impor-
tant for the protective effect seen with alcohol
consumption. This finding is similar to that of another
recently reported study which found that NAFLD
patients who had abstained from alcohol had a signifi-
cantly higher risk of having advanced fibrosis (26). In
this study, patients with longer duration of abstinence
had significantly higher amounts of total body fat
and a trend to having more features of metabolic
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syndrome. Whether these features played a significant
role in disease severity could not be adequately
assessed in this study.
The role of some alcohol consumption in protecting
against fibrosis progression is not well understood. NA-
FLD has been shown to be associated with insulin resis-
tance and more common in patients with metabolic
syndrome. Mild to moderate alcohol consumption has
been shown to decrease insulin resistance and improve
components of metabolic syndrome (27). This poten-
tially may explain the effects of small amounts of alco-
hol use in mediating these protective effects and
thereby associated with less histological injury in
patients with NAFLD. It is interesting to speculate that
ongoing alcohol consumption in small amounts might
influence disease severity over time. In the study by
Cotrim et al., light alcohol consumption was associated
with decreased prevalence of insulin resistance (10).
Gunji and colleagues recently published a study of
1902 individuals with fatty liver diagnosed by ultra-
sound of whom 249 participants were insulin resistant
(defined as HOMA-IR ≥2.5) (28). Compared to non-
drinkers, light, moderate and heavy alcohol consump-
tion was inversely associated with HOMA-IR scores
and this effect of alcohol on HOMA-IR was indepen-
dent of metabolic syndrome and presence of fatty liver
on ultrasound. In this study, although there was a
trend towards lower insulin resistance in the higher
consumption group, this difference did not reach sta-
tistical significance. However, the effect on insulin sen-
sitivity appears to be more a function of body mass
index and central adiposity (29) rather than just alco-
hol alone. Moreover, whether there is a threshold of
alcohol consumption that is associated with improved
insulin sensitivity independent of features of metabolic
syndrome is not known.
The limitations of this study were the sample size and
importantly patients with overall mild disease. With a
larger study and a broader spectrum of NAFLD histo-
logical scoring we may see a more clear association
between alcohol consumption and its effect on insulin
sensitivity and features of metabolic syndrome and the
relationship to disease severity on liver histology. The
lifetime alcohol consumption history although obtained
at the time of enrolment of this prospective study, is
based on retrospective review of alcohol consumption
over a long time with the patients and although an
attempt was made to increase accuracy by including life
events, it relies on recall and there may also be over or
underreporting.
In conclusion, among patients with clinical and his-
tologically defined NAFLD using stringent criteria, some
alcohol consumption appears to have an independent
protective effect on fibrosis severity. Larger studies with
a wider spectrum of histologically well-defined NAFLD
and well-determined alcohol consumption are needed
to better delineate the true effect of alcohol independent
of other risk factors for disease progression.
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